ArticleAmerican journal of translational research2019
Synergistic effects of
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- The interplay between probiotics and host autophagy: mechanisms of action and emerging insights.Autophagy · 2025Review
- Innovative mesenchymal stem cell treatments for fatty liver disease.World journal of stem cells · 2024Article
- Recent Advances in Mesenchymal Stem/Stromal Cell-Based Therapy for Alcohol-Associated Liver Disease and Non-alcoholic Fatty Liver Disease.Stem cells translational medicine · 2024Article
- mTOR Signaling Pathway and Gut Microbiota in Various Disorders: Mechanisms and Potential Drugs in Pharmacotherapy.International journal of molecular sciences · 2023Review
- Cell-Free Supernatant Derived from aBiomedicines · 2023Article
- The gut microbiota: A new perspective for tertiary prevention of hepatobiliary and gallbladder diseases.Frontiers in nutrition · 2023Review
- Mesenchymal stem cells-based therapy in liver diseases.Molecular biomedicine · 2022Review
- ProbioticFrontiers in microbiology · 2022Article
- Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease.Frontiers in bioengineering and biotechnology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota has been shown to play an important role in chronic liver disease. It has been found that both
Indexed as
Identifiers
31632541PMC6789285W2991181584What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.